Cystic Fibrosis: could the microbiome change everything?

#CysticFibrosis  #Microbiome  #InnovativeTherapies  #Probiotics  #LungInfections  #PrecisionMedicine

Cystic fibrosis is a severe genetic disease caused by mutations in the CFTR gene, disrupting ion transport and leading to thick mucus accumulation in the airways. Despite advances with CFTR modulators, these treatments remain inaccessible to some patients and do not completely eliminate chronic infections or prevent lung damage.

Given these limitations, the respiratory microbiome is attracting growing interest. Recent studies suggest that altered microbial diversity in the lungs may encourage opportunistic pathogens and worsen disease progression. Exploring microbiome-based therapeutic approaches opens promising avenues to slow the progression of cystic fibrosis.

Microbiome and cystic fibrosis: a winning duo?

This study reviews current knowledge on the interaction between the airway microbiome and cystic fibrosis. Researchers analyzed different approaches, including:

• Oral probiotics, some of which have shown beneficial effects in reducing pulmonary exacerbations.
• Local administration of probiotics in the respiratory tract, an innovative strategy aimed at restoring microbial balance and limiting pathogen proliferation.
• Links between the microbiome and pulmonary inflammation, to better understand how commensal bacteria may play a protective role against infections.

The results indicate that certain probiotic strains, administered orally or directly into the airways, may rebalance the lung microbiome. This could limit opportunistic pathogen proliferation while reducing chronic inflammation. Such interventions could improve lung function and slow the progression of recurrent infections, a key challenge in managing cystic fibrosis.

However, clinical data remains limited. Most trials conducted so far are preclinical or small-scale, and the precise mechanisms by which probiotics influence the pulmonary environment are not yet fully understood. Large-scale clinical studies are needed to assess the true effectiveness of these approaches, identify the most suitable strains, and establish optimal administration protocols. Additionally, safety concerns must be rigorously analyzed to prevent potential risks, such as excessive colonization or negative interactions with common antibiotic treatments.

Read next: Cystic Fibrosis: the era of personalized treatments

Rebalancing the microbiome: a hope for the future

Cystic fibrosis is a severe genetic disorder characterized by the accumulation of thick mucus in the airways, promoting chronic infections and inflammation. While CFTR modulators have been a major breakthrough, these therapies are not accessible to all patients and do not completely prevent persistent infections or long-term lung deterioration.

This study explored the potential of microbiome-based therapies in cystic fibrosis, evaluating their impact on pulmonary inflammation, infection prevention, and complementarity with existing treatments. By targeting the microbiome, these approaches could offer a preventive strategy to slow disease progression and improve patients’ quality of life.

Findings suggest that microbiome modulation—through probiotics, prebiotics, or microbiome transplants—could correct microbial imbalances and reduce chronic inflammation. However, several challenges still hinder the clinical application of this therapeutic approach.

Standardizing probiotic treatments and better understanding the impact of CFTR modulators and antibiotics on the microbiome are essential for optimizing these strategies. Antibiotics, while necessary, disrupt microbial balance and promote antibiotic resistance. Combining CFTR modulators with microbiome-based therapies could provide a more preventive and effective approach to managing cystic fibrosis.  

Read next: The role of probiotics in respiratory tract Infections in children